2.5 million euros for five research teams from Bavaria
. 5 million euros funding for innovative projects in biomedicine The research projects address the topics: Hepatitis-B…
. 5 million euros funding for innovative projects in biomedicine The research projects address the topics: Hepatitis-B…
. New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31,…
The International Congress on Particle Technology (PARTEC) will take place in Nuremberg from 26-28 September 2023. This…
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 mi…
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox ou…
Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2022. The consolidated, audited results were in li…
Adds two revenue-generating vaccines for the prevention of cholera and typhoid fever that will establish Bavarian Nordic…
Der aktuelle Vogelgrippe-Ausbruch bei Säugetieren in Spanien zeigt das Potenzial des Grippe-Virus für eine Pandemie mit…
TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph no…